Antibody (Suitable for clinical applications)
Sample Type: FFPE Patient Samples.
Tested Applications: IHC. Approved for In Vitro Diagnostic Procedures on FFPE tissues. For tissue collection recommendations, please see datasheet sent with product.
|Recommended Dilution (Conc)||1:50-1:75|
|Pretreatment||Citrate Buffer pH 6.0|
|Incubation Parameters||30 min at Room Temperature|
Prior to use, inspect vial for the presence of any precipitate or other unusual physical properties. These can indicate that the antibody has degraded and is no longer suitable for patient samples. Please run positive and negative controls simultaneously with all patient samples to account and control for errors in laboratory procedure. Use of methods or materials not recommended by enQuire Bio including change to dilution range and detection system should be routinely validated by the user.
Anti-Cytokeratin 5 Antibody Clone: XM26
Host and Isotype: Mouse IgG1, kappa
Recommended Positive Control Sample: Skin
Cellular Localization of Antibody XM26 Staining: Cytoplasmic
Buffer and Stabilizer: PBS with 1% BSA and 0.05% NaN3
Antibody Concentration: Lot specific. Plese contact tech support for data.
Immunogen: BALB/C mice were injected with prokaryotic recombinant protein corresponding to 103 amino acid portion of C-terminal region of the human cytokeratin 5 molecule.
Storage Conditions: This antibody should be stored refrigerated (2-8°C). This product should not be used past the expiration date printed on the vial.
Cytokeratin 5 Information for Pathologists
Summary:Molecular weight is 58 kDa. Major partner is CK14, but related to cytokeratin 6 (antibodies are often to CK5/6). Common antibody is 34BE12. Mutations may cause epidermolysis bullosa simplex (Hum Mutat 2006;27:719), Dowling-Degos disease (Am J Hum Genet 2006;78:510). Important in tooth enamel formation (J Biol Chem 2003;278:20293).
Common Uses By Pathologists:Helps defines a basal-like subtype of invasive ductal carcinoma of the breast that is usually CK5/6+, ER-, PR-, HER2-, EGFR+ with poorer prognosis (Clin Cancer Res 2006;12:1533); associated with premenopausal African American women (JAMA 2006;295:2492), BRCA1 (J Natl Cancer Inst 2003;95:1482, Mod Pathol 2005;18:1321) and brain metastases (Am J Surg Pathol 2006;30:1097). Defines a DCIS subtype with poorer prognosis (Hum Pathol 2007;38:197). Distinguish breast usual ductal hyperplasia (strong staining) from solid papillary DCIS (negative, Hum Pathol 2006;37:787). p63+ and CK5/6+ poorly differentiated metastatic carcinomas are likely to have squamous carcinoma primaries (Am J Clin Pathol 2001;116:823). Distinguish epithelioid mesothelioma (CK5/6+ cytoplasmic staining with perinuclear enhancement) from lung adenocarcinoma (usually CK5/6 negative, Histopathology 2006;48:223); also in pleural effusions (Diagn Cytopathol 2006;34:801).
Limitations and Warranty
This antibody is manufactured in accordance with clinical good manufacturing practices in an ISO13485:2016 certified production facility. It is intended for multiple uses including in vitro diagnostic use and research use only applications. Please see vial label for expiration date. We strive to always deliver antibodies with a shelf life of at least two years.
There are no reviews yet.